http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012127124-A9
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f08a7dd141d8b0e7453e2ac67360eeda |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate | 2011-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3a933106b7f16a2f191e72605337dd4 |
| publicationDate | 2012-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2012127124-A9 |
| titleOfInvention | Tests dedicated to oncology and to neuro-oncology |
| abstract | The present invention relates to novel polypeptide, ribonucleotide and nucleotide sequences to be integrated into a novel test for screening for reinduction of the cell cycle targeting oncology, and to the use of some of these same functionalized sequences as an adjuvant treatment by molecular targeting. It is a major improvement without which the diagnosis and the pharmacodiagnostic test could only be partial. The consequence of this would be a less effective treatment with a narrower application according to the heterogeneity of cancers. It is therefore a diagnostic test and a prognostic test for various cancers. More particularly, the invention relates to the use of the genes or of the proteins of the LIV21 complex and also derivatives thereof as therapeutic tools and as diagnostic and prognostic markers for cancers. The invention therefore relates to the detection of the LIV21 gene or of the LIV21 protein with a kit comprising antibodies or probes specific for LIV21, but also the invention is the use of all the proliferation markers and transcription factors which play a role in the cancerization and, for some, neurodegeneration process. Therefore, the invention lies in the use of RT‑PCR and of quantitative PCR (Q PCR) twinned with the fabrication of diagnostic DNA chips, diagnostic protein chips and diagnostic antibody chips comprising the known antibodies for the various proteins of the protein complexes associated, according to the cell cycle phases, with the LIV21 complex, i.e., without restriction thereto: peptides of and antibodies for RBP2, E2F4, E2F1, SUMO, HDAC1, crb2, Int2, cmd2, cycE/cdk2, cdk1, CREB1 and p300, Rb, p107 and p130 of the pocket proteins family, but also NF-κB, cdc2A, mdm2, p21, p53, p65, BRCA1, TNFalpha and TGF beta. The novel sequences are the polynucleotide and polypeptide sequences of Liv21F, Liv21H, etc. (additional listing: SEQ ID No. 171 to 185 ...) and the sequences of corresponding genes, proteins and antibodies newly integrated into the pharmacodiagnostic biochips. |
| priorityDate | 2011-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1020.